Cellares has entered an expanded agreement with Bristol Myers Squibb to provide proof-of-concept manufacturing for a second CAR-T cell therapy.

The latest move comes after Cellares first indicated that Bristol Myers Squibb had entered the Cellares technology adoption partnership (TAP) programme to assess cell therapy asset manufacturing on its automated Cell Shuttle platform.

Bristol Myers Squibb will now have an additional opportunity to investigate the Cellares platform for commercial-scale manufacture.

Cellares will be responsible for optimising, automating and the tech transfer of the additional CAR-T cell therapy process onto its Cell Shuttle platform.

Utilising the programme, Bristol Myers Squibb will assess the platform as an automated manufacturing process and produce comparability data to confirm whether it is a viable, cost-efficient and scaleable manufacturing solution for cell therapies.

As developers of cell therapies look to implement the Cell Shuttle platform as a clinical and commercial-stage GMP [good manufacturing practice] solution, demand is growing for the TAP programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

This programme allows the automation of manual processes and the tech transfer onto the platform in only six months.

Participating cell therapy developers will also be able to tech-transfer their cell therapy processes onto a Cell Shuttle at any stage.

Cellares CEO Fabian Gerlinghaus stated: “We are excited to expand our relationship with Bristol Myers Squibb even further beyond the Series C investment and the first TAP programme for cell therapies.

“The optimisation and automation of this additional CAR-T cell therapy process through our TAP programme expands on our first partnership with BMS and helps our mission to accelerate access to life-saving cell therapies for patients.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.